Thank you, welcome everybody to the presentation of the Nolato's second quarter of 2021. I'm starting on page two in the handouts. We had a new record quarter for the Nolato group, with the sales close to SEK 2.8 billion, giving an organic growth of 11% during the quarter. The GW Plastics acquisition, which we acquired 1st of September, showed a strong performance quarter on quarter. We had an operating profit of SEK 336 million, giving a 25% increase of operating profit, if we compare to second quarter last year. We reached SEK 336 million, creating a margin of 12.1% during the quarter. The cash flow after investments amounted to SEK 346 million during the quarter. Turning to page three. On this page, we can see the balanced group with three strong business areas. All three business areas have a good global reach, and each with operations on three important continents. Turning to page four, focusing on the Medical Solutions. With the Medical Solutions, we are on a global expansion journey, where we are seeing a continuous growth over the 20 years we show here on this page, and our growth is continuing, and we are building our footprint on the important places around the globe. If we turn to page five, showing some of our focused product areas. We have six important therapeutical areas that we focus on. We start with IVD, in vitro diagnostics. It's a future interesting area with good potential for growth. We see, however, at the moment, there is some shortages of capacity in the total market. The next one is cardiology, mostly consisting of long-term implants for different type of pacemakers or heart supporting devices. We have pharma, that consists of liquid and solid drug containers. Continence care, which is a very large area with very high volumes. We have our general surgical area, which, of course, during the pandemic now has been affected with some postponed surgical across the globe. The last of the six focused product areas is the drug delivery, which is an interesting area with delivery devices, mostly focused on large molecule drugs, the sort of bio-based drugs. If you turn to page six, focusing on the numbers for the quarter for Medical Solutions. During this quarter, we saw a 2% increase of our sales if we adjust for currency and acquisitions. Overall, we saw a general good demand, but available capacity is a limiting factor within the diagnostic area. We saw a quarter-on-quarter increase in the surgical area, the pandemic is still having an effect. We saw strong performance by the acquired business of GW Plastics. During the quarter, we had sales just above SEK 1 billion, and an operating profit of SEK 124 million, creating a margin of 12.1%. The margin is, of course, seeing some diluted effect from the acquired U.S. business, if we have in comparison to last year before the acquisition. Our expansion of production capacity is according to plan. We are currently expanding in Switzerland, Hungary, Poland, United States, and Sweden. If we turn to page seven, focusing on Integrated Solutions. Within our Integrated Solutions business area, we are in an expansion into new markets. We are expanding ourselves in different market areas, and we initiated that expansion some five years ago, creating good growth for us. We turn to page eight. If we look a little bit deeper into the Integrated Solutions business area, we have two parts to the business area. We have what we call consumer electronics, consisting of vaporizing heating products, different electronic devices, could be connected Wi-Fi system, wearables, and those kinds of things. That part is the largest part of the business area. This second and smaller area would be the EMC & Thermal. This area we have built up within the telecommunication, and now we are expanding this to the other segments of the market, such as the automotive and other industries. Turning to page nine, looking at the numbers and the details of the second quarter. During this quarter, we had a strong growth with 12% currency-adjusted growth during the quarter. We saw strong growth in the VHP with increased volumes. We had solid EMC volumes during the quarter. We had high comparative numbers for the quarter within the EMC, but we see some very good initiatives in the automotive rollouts, and good quarter for the business area. If we look a little bit ahead into the next quarter, we see good sales growth, expect that for third quarter, both within the VHP and the EMC part of the business. The margin during the quarter ended up at 13%. If you're in the comparison number for second quarter 2020, we had some positive impact by a contribution for Chinese authorities. The quarter ended up just shy of SEK 1.2 billion in sales and a profit of SEK 154 million. Turning to page 10, focusing on Industrial Solutions. Within the Industrial Solutions business area, we are on a technology and geographical expansion journey. During the last year, we have expanded our operations. We're now present on three important continents with this business area. On page 11, we see the split up of the business area in two different segments. We have the general industry focusing on different industrial customers doing a lot of different things. It could be white goods, forest equipment, furniture, all kinds of different things. The other part is the automotive part, where we are focusing on the sort of high-end technology advanced things for automotive, both light vehicles and heavy vehicles. If we turn to page 12, we saw a strong increase in sales, a 22% growth for the industrial, but we should remember that the comparison quarter last year was very weak due to the pandemic and the close down of some automotive manufacturing sites. We saw a slightly negative impact of component shortages, mostly within the automotive sector. We ended up with SEK 580 million in sales and the operating profit of SEK 62 million, creating a strong margin of 10.7% for the business area. Good afternoon. Per-Ola Holmström to comment group financial highlights on page 13. The net sales increased 11%, adjusted for currency and acquisitions to almost SEK 2.8 billion. The operating profit, EBITDA, if we do exclude the non-recurring item of SEK 50 million, was SEK 336. In these numbers, you can see the non-recurring item included. The EBITDA margin, excluding the non-recurring item, is 12.1%. To give a short summary of that non-recurring item, that is prior to the acquisition of GW Plastics, which has been consolidated from September 1. They applied for a loan that could be received from U.S. authorities to provide support during the pandemic. Under certain conditions, the loan may be remitted, as announced by the authorities during this second quarter. The effect of this is recognized in the income statement as other income at group level, and the amount does not affect the earnings of the business areas. It has no cash flow effect for Nolato, and it is also tax-free. From these two aspects, it's quite easy to exclude it. It's reported according to IFRS rules. The profit after tax was SEK 291 million compared to SEK 207 million, and the effective tax rate was 20% for the first six months compared to 19.7% for the same period last year. The cash flow after investment ended up with SEK 417 million compared to SEK 612 million. Last year, we did have a short temporary reduction in tied-up working capital during the first half year. As we have estimated earlier, CapEx will increase for 2020, and the first half year increase from SEK 133 million to SEK 332 million. We expect now CapEx to be around SEK 700 million for the full year 2020. The net financial liabilities was, if we exclude pension and lease liability amounts, SEK 194 million, and has decreased further from SEK 298 million at year-end. We have, during the Q2, paid out SEK 428 million in dividends to the shareholders. We do have a strong financial position. Turning to page 14, focusing on the current situation for our business area, starting with Medical Solutions. We are maintaining our growth strategy, a lot of focus on innovation based on strong customer relationship. We have seen, and still see some impact of the pandemic, and we are achieving synergies across the markets. Within the Integrated Solutions business area, we have established a strong position within new product areas based on our flexible production structure. We see the five-year rollout and the new initiatives in the automotive sector that are positive for our EMC & Thermal part of the business area. Within Industrial Solutions, we have advanced our market positions. We see efficiency improvements. We have, of course, impact of the pandemic. A lot of emphasis on sustainable solutions within this business area. We would now open up to questions. Thank you. If you do wish to ask a question, please press 01 on your telephone keypad. If you wish to withdraw your question, you may do so by pressing 02 to cancel. Our first question is from Carl Ragnerstam of Nordea. Please go ahead. Hi, it's Carl from Nordea. A couple of questions from my side. Firstly, on Medical Solutions, you mentioned that you see sequential improvement in the surgical segment and capacity constraints for testing equipment. First, on the surgical side, is it possible to give some flavor on the magnitude of your recovery and whether you have seen a gradual recovery during the quarter, given increased vaccination levels? Also, sorry, when it comes to the sort of testing side, if it's you experiencing capacity constraints or is it your suppliers, or is it difficult to find materials? Just you can clarify that as well. Okay. Thank you, Carl. I start with the surgical recovery, we have seen a gradual recovery during the quarter. I still consider the volumes to be lower than normal as an overall perspective, but gradual improvements. On the IVD and the diagnostic sector, the constraints is, if you look on the total market, there is a lack of capacity in converting and producing these products. It's not lack of raw material or anything like that, it's a lack of total installed capacity. Okay, it's not from your side then, I guess. It is. In our factories, we are running as much as we can in the installed capacity. Okay. It might be a problem for the coming two quarters as well, I guess then. I think it's a problem for the whole area as such, and the total installed capacity in the world is not enough for the demand at the moment. I think you could add as well for our sake that, as we do say in this report, and we said that before as well, we are installing, of course, more capacity. That is something that we bring on gradually. When will you have new capacity? Is it a short-term add or is it more of a mid-term? That is something that is coming gradually. We have some additions which will affect quite quickly. Of course, there are some in the plans going forward. It's an ongoing thing, gradually improved. I guess, what is your best guess when it comes to the surgical segment returning to growth? What's your best guess there? Is it in the coming quarter or six months, or do you have any view on that? My best guess would be gradually during the rest of the year. Returning to growth in H2, then? Yeah, there is two factors affecting this. First, of course, the surgical procedures need to come up to a normal stage. There is a lot of the components and equipment in pipeline. It's two things. It's difficult to say how it will play out. Okay, perfect. Also on the heated tobacco guidance or Integrated Solutions guidance, more specifically, you guided for good growth sequentially. Given that your growth has been 40%, 50% the past two quarters, is it fair to assume that your definition of good growth is at least double digits? Then also, do you expect EMC to grow at the same or faster pace than heated tobacco in your guidance? We have been a bit more, let's say, specific for a number of quarters back. The reason for that has been, of course, that it has been a bit more volatile in that segment. We did feel that the Q2 numbers we did see would be a good base, and now we didn't be that specific that we have been. That is, of course, the view that we have of the second quarter as a base. You mentioned double-digit growth, and we would agree to that, double digits in the low part of the double digits. About EMC, we do see the same kind of growth in that area. It's a good growth situation. Okay, perfect. Very helpful. Thank you. Thank you. Our next question is from Mikael Laséen of Carnegie. Please go ahead. Hi. I got a couple of questions. This supply chain and component shortage issues that you have in the industrial segment, can you talk about this maybe more in detail and say something about the revenue and EBIT impact? Yes. We have seen some lack of components for the automotive industry during the quarter. It has had a slight impact, I would say, during the quarter for Industrial, but still some. Okay. Do you know how much it affected the top line? It's hard to say in exact numbers because we don't have really something to compare with. You have seen that some of the automotive factories have closed down for shorter time periods. Some of that has been then increasing orders the next week, and so on. Our estimation is still that there is a slight effect on the negative side during the quarter. What do you expect going forward? Is the outlook better, more stable, or will this continue? What would you expect? I think you could say that there will be some effects going forward as well. You can read about it in some of the reports, and you can read about it in the papers from time to time. I think we have had customers affected less than many of them, and also the delivery addresses we have had has been maybe not the worst ones. A favorable situation compared to many others. Of course, you could say that in the end, there is a good demand, and some of the customers, they plan for producing the need and the demand at a later stage, which could be then on the positive side. Probably there will be some smaller effects also going forward. Okay. Just my final question on the industrial side, I have one more if it's okay. The basic question about the split between automotive and the other segments, the other customer types. On the automotive segment, how much is the trucks and cars? The automotive sector is about 35%, 40% of the business area and has been quite stable. Our part is mainly to the light vehicles or cars. That is the largest part for us. Okay. I was just curious because the picture showed yesterday it was 50/50, so I was a bit surprised. Just a follow-up there, how much of the light side is battery electric, or everything in the automotive side? I would say if you include hybrids within this, then I would say the majority would be hybrid today. Okay. Pure battery electric? I don't have the number for the split between the full electric and hybrid. Sorry about that. Okay, that's fine. All right, my final question is on GW Plastics. Great to know that it's starting to grow again. What type of growth rates are you seeing there? If you also can tell us how much revenue contribution that you got from GW this quarter? Yes. The growth rate was double digits for GW if you compare to the first quarter this year sequentially. The sales number was about SEK 390 million for GW Plastics. Okay, got it. Is it okay if I ask one more? Yes. Okay, great. It's about this comment that you made about Integrated, especially VHP and EMC. You also said something there about component shortage. Is the growth double digits excluding this, or how should we think about the component shortage side? I think we've seen some tendency to some disturbances in the delivery of components for Integrated during this quarter. The comment for the future should be more in a general view that there is a shortage total in the market. We expect to be able to deliver this low double-digit growth. Okay, great. Got it. Thanks. Thank you. Just a reminder, if you wish to ask a question, that's 01 on your telephone keypad. There'll be a brief pause while any further questions are being registered. There are no further questions. I'll hand back over to our speakers. Thank you for your interest in Nolato's presentation of second quarter. I wish you all a very nice summer. Thank you.